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INTELLECTUAL PROPERTY STRATEGY IN
BIOINFORMATICS AND BIOCHIPS
Dennis Fernandez and Mary Chow
I. INTRODUCTION
What are the fields of bioinformatics and biochips? These are
relatively new disciplines that have gained much recognition in the
past few years. Basically, bioinformatics is the convergence of
analytical and computational tools with the discipline of biological
research. This has vast influence in biological research, as numerous
data that are collected through laboratory experiments can be
organized and analyzed, and predictions can be made to reduce the
time spent in finding cures for the causes and cures of diseases.
Additionally, biochips pertain to primarily semiconductor-based
devices used for biological or other healthcare-related applications.
The amount of data collected in biological research is
tremendous especially in the area of genomics. On June 26, 2000, a
group of scientists announced the completed survey of the human
genome-the sum total of all the genes in each cell of the human
body.' The genome is the entire genetic blueprint for a human being
written in the alphabet of chemical compounds called nucleotides:
adenine (A), guanine (G), cytosine (C), and thiamine (T).2 A gene is
the specific sequence of the nucleotides that tells the body how to
create proteins that maintain cellular structure of the organism and
direct the functions of the cell.3 The human cell has some 100,000
genes that are specific sequences of DNA and the sum total of all
units of nucleotides results in a mind-boggling 3.1 to 3.2 billion base
pairs in the human genome.4 However, only 3%-5% of the genome
contains genes, which in turn produce four to five proteins. These
few protein molecules control all of life's major functions.5 Thus,
1. Stephen A. O'Neil, Mapping the Human Genome, HILLARDS LYONS EQUITY, Aug.
21, 2000.
2. Id.
3. Id.
4. Id.
5. Stephan Herrara, Patent Panic, RED HERRING, July 2000, at 208.
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computational technology is required in the sequencing of the
database, the studying of the functions of the specific sequence
(gene), and the management and dissemination of the genetic
information.
With the potential pay-off of finding a blockbuster drug or
treatment, a copious amount of funding, both private and public, has
gone into the development of bioinformatic tools as well as related
biochip applications in the genomic space. With all the money going
into these bioinformatic and biochip companies, these companies
need to protect their technology. In 1999 alone, for example, 289,448
patent applications were filed in the bioinformatic field and the
United States Patent and Trademark Office (USPTO) has created
working groups to deal with the influx of bioinformatic applications.
6
Although patents in these areas have increased and provided an
avenue to protect one's intellectual property in this discipline,
controversy surrounds the patenting of various technologies in the
field. For one, the thought of allowing a company to patent and have
a monopoly over a gene sequence that has been around since the
beginning of life is quite disturbing. On the other hand, the
discovering and developing of a new gene-based pharmaceutical
product in the United States requires years of commitment and
immense capital resources, possibly in the realm of $500 million.7
Without the protection of the patent system, these companie would
have no means of recouping these capital and time investments, and
innovation would be put to a halt.
8
II. INTELLECTUAL PROPERTY PROTECTION IN GENOMIC DISCIPLINE
Within the genomic discipline, companies and research can be
divided into three areas: 1) sequencing the genome, 2) functional
genomics, which is finding the functions of the genes, and 3)
information systems, which is the software tools that manage and
present the tremendous amount of data. Additionally, various
biochips technologies, such as micro-arrays, are deployed in
cooperation with such genomic tools. For each area, different
technology is generated and thus, a different intellectual property
strategy should be deployed. Often, companies participate in one or
6. Margaret M. Parr, Patenting Bioinformatics Inventions, The USPTO Comes to the
Silicon Valley Slide Presentation (April It, 2000).
7. William A. Haseltine, The Case for Gene Patents, MIT TECH. REV., Sept.-Oct. 2000,
at 59.
8. Id.
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more of the areas and should pursue a joint strategy.
A. Sequencing the Genome
With the hype surrounding the completion of the Human
Genome Project, new technology has been developed for decoding
DNA that provided for the rapid discovery of gene fragments known
as expressed-sequence tags (ESTs).9  Companies such as Incyte
Genomics and Celera have generated large databases of expressed
sequence (EST) data and have aggressively filed patents on these
ESTs. For example, Human Genome Sciences holds patents on 103
human genes and has patents pending on 7,500 genes. 10 Incyte
Genomics tops the list with some 400 patented genes, while Celera,
which only began decoding DNA last year, has already filed patent
claims on at least 6,500 gene sequences."
To fall within patent protection, an invention must be deemed
novel, useful and non-obvious.12  Often the biological function of
.these DNA sequences are unknown and companies have tried to
fulfill the useful criteria by proposing generic and often frivolous
uses, such as forensic probes and sometimes even cattle feed.
13
Currently, Incyte and similar companies have filed thousands of
provisional patent applications with the USPTO for ESTs in hopes
that they will someday be able to find the "usefulness" of the
sequence. 14 Numerous opponents of these tactics have argued that
patent rights should be reserved for whomever uncovers the true
biological function of a complete gene.' 5 The USPTO is currently
developing guidelines that require examiners to reject patents that
don't describe a "specific, substantial and credible" use for a DNA
sequence.' 6  Thus, many experts predict that most of these EST
patents would eventually not receive patent protection.
7
To combat the high risk that their patent applications would not
be allowed, companies in this area can pursue various strategic
options. One of which is to challenge the examiner's rejection by an
appeal to the PTO board of appeals. However, if the appeal process is
9. Antonio Regalado, The Great Gene Grab, MIT TECH. REV., Sept.-Oct. 2000, at 48.
10. Id.
11. Id.
12. 35 U.S.C. §§ 101-103.
13. Regalado, supra note 9, at 53.
14. Herrera, supra note 5, at 210.
15. Id.
16. Id.
17. Id.
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not successful, the case can be taken to the Court of Appeals for the
Federal Circuit, where the new "usefulness" standard has not been
tested. 18 Currently, "usefulness" is defined as something "beneficial
in contrast to injurious to the morals, health, or good order of
society."' 19 Thus, the Federal Circuit would need to justify the
requirement of the newly proposed "specific, substantial and credible
usefulness standard.,
20
Another strategic move would be to fortify an application by
performing homology studies on the gene sequence in the patent.
Homology refers to the establishment of a relationship or common
thread between the novel gene sequence in the patent to another gene
that has already been discovered, but not patented. 21 For example, a
claim that gene XYZ is related to ABC, which has a known function,
thus, making the argument that gene XYZ performs a related function
to gene ABC's function. The standard upon which the USPTO relies
on is that an expert in the field would agree that the common thread is
22strong. However, as our understanding of genes increases, the
existing definition of what is related is constantly shifting and various
patents may be invalidated based on these shifts.23
Another tactic would be to conduct several functional assays in
order to better determine gene sequence function. The inventor can
submit a declaration on sequences behavior asserting that he or she
has a strong notion that the sequence is more likely than not to have
some function.2 4 Even if a DNA discovery claims to encode a protein
involved in cancer but later on turns out to be involved in another
disease, the courts would allow the new usage and the invention is
protected.25 For example, Viagra was originally patented as a heart
remedy.
26
The most conservative approach would be to go back to the
laboratory and perform analysis until the inventor found a definitive
function. However, when you do find the function, the genetic
sequence probably would have been published already and you will
be too late in the game to claim the use of the genetic sequence.
18. Id.
19. Herrera, supra note 5, at 210.
20. Id.
21. Id.
22. Id.
23. Id.
24. Id.
25. Herrera, supra note 5, at 210.
26. Id.
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With the controversy surrounding the patenting of just the
sequences, companies in this area should explore protecting
intellectual property surrounding the tools to sequence the genes and
the tools to analyze the genetic data. Patents in this category
generally cover computer-implemented methods, computer-based
systems, and computer programs for analyzing and annotating
voluminous nucleotide sequences." For example, protecting a
company's proprietary method of locating boundaries between exons
and introns would create value in licensing revenue and also, more
importantly, the protected intellectual property can be used as
bargaining chips in a cross-licensing of another company's
28technology. Many of these analytic tools are embodied in software
and thus would get automatic protection from copyright protection for
its source code. However, patent protection is a better venue as the
functionality of the invention is protected versus the literal source
code. For example, if a company obtained a patent for its method of
locating boundaries between exons and introns, one who practices one
of the steps covered in its patent claims would be an infringer even if
a different source code is utilized.29 Under copyright protection, the
infringer would need to use the exact source code to infringe.
B. Functional Genomics and Biochips
After acquisition of specific sequences, the functionality of these
sequences need to be determined to generate value in creating targets
for new drugs and new genetic therapy treatments. Many players
compete in this area using bioinformatics and biochip tools, as the
monetary and emotional pay-off is tremendous if one is able to be the
first to find a cure to a certain disease.
Once again the importance of computational power is put into
play as computational methodologies are deployed in comparative
genomic,3° the comparing of human genetic data to other organism
genomes, which have functions that have been defined. Patent
protection would be invaluable in protecting methods and related
biosensors for sequence alignments, homology searches, and
metabolic pathway modeling.31  Protecting these fundamental
27. Wong et al., Genomics-Based Intellectual Property Portfolios, MORRISON &
FOERSTER, LLP, October 14, 1999, at 3.
28. Id.
29. Id.
30. Wong, supra note 27, at 3.
31. Id. at 5.
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methods and devices would create more value than patenting a
specific software product, as intense competition in this area would
create shorter and shorter product life cycles.
Genes do not work in isolation. Finding the pattern of gene
expression is another great area of interest that requires computational
power. Biochip companies, such as Affymetrix and Hyseq, are
engaged in developing assays, tools, and computational techniques for
detecting, monitoring, and interpreting gene expression profiles.3 z
For example, a microarray, a collection of short sequences of
nucleotide synthesized to hybridize with the genes of interest, are
placed in a grid on a glass slide or chip and exposed to a sample of
unknown DNA.33 A fluorescent "signaling" enzyme is attached to the
end of the probe that glows when the probe hybridizes with the gene
of interest. 34  Affymetrix, which pioneered the concept of DNA
microarrays based on computer chip technology, can fit 250,000
probes in a matrix only 1 square centimeter in size.35  With an
estimated 100,000 genes in the human body, a "universal" microarray
is within reach. Incyte Genomics has announced that its Synteni
division has intends to make a chip containing the entire human
genome in the next few years.36
To protect their intellectual property, companies in this area need
to seek patent protection covering the core technology of these
devices and methods. However, an even more valuable claim would
be to protect the generation of expression data utilizing these methods
and devices. In addition, since the design of the microarrays mirrors
chip design technology, another method of protection to explore
would be maskwork protection. In chip technology, when the chip
layout includes an original circuit design, the layout is protectable. 37
Specifically, maskworks protect against the unauthorized copying of
chip layout information. 38 Federal registration is relatively quick and
an inexpensive process, but filing must be done within two years of
commercialization of the chip product. 39 Thus, it is arguable that the
32. Id. at 3.
33. CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO IPO: THE BUSINESS OF
BIOTECHNOLOGY 74 (2001).
34. Id.
35. Id. at 76.
36. ROBBINS-ROTH, supra note 33, at 76.
37. Mary Chow & Dennis Fernandez, Intellectual Property Rights in Bioinformatics,
FERNANDEZ & ASSOCIATES LLP, 1999, at 2.
38. Id.
39. Id.
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layout of the probes for a microarray can avail itself with maskwork
protection.
C. Information Systems and Bioinformatics
As more information is generated from sequencing tools and
functional analysis tools, the managing and sharing of the information
becomes increasingly important. The ability to share, manage, and
distribute the information is extremely important in this space because
ethical issues create an environment that fosters sharing of the
information and suppresses the patenting of the information. Already
there are advocates who call for an intellectual property free zone for
genomic research, a moratorium on gene patenting, and a compulsory
licensing scheme.4 ° In March 2000, President Clinton and Prime
Minister Blair made a joint announcement that human genome
research "should be made available to scientists everywhere. ' 4 1 Thus,
a company should not concentrate all its intellectual property
protection on the information, the genetic sequence, but instead
should try to create value in the analytic tools and the management of
the information.
Bioinformatics companies, such as Incyte Genomics, Celera, and
CuraGen, are developing Internet tools to allow researchers to share
the genetic information in their databases. Also, these companies are
providing researchers various tools to analyze the data, present the
data, and store their research results. This revolution toward content
delivery and presentation can be compared to the Internet revolution
where content is free but the added value is the presentation. Thus,
there is a "silent gold rush in the genomic space" that mirrors the rush
to file Internet business method patents, such as Amazon's "one-
click" method.42 Numerous companies are filing patents to stake out
methods for sharing and manipulating the enormous quantity of
genetic data being put online. For example, one application claims
the idea of using a reward system to compensate scientists with free
purchase for posting information and comments to a private gene
database.4 3 However, patenting business methods would bring about
the same controversy that surrounds the current Internet patents as
opponents are arguing that these methods of manipulating research
40. Seth Shulman, Toward Sharing the Genome,. MIT TECH. REV., Sept.-Oct. 2000, at
60-67.
41. Id.
42. Regalado, supra note 9, at 51.
43. Id.
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data online have been utilized in the research space for a number of
years." Thus, a patent portfolio should include protection of the
enabling tools as well as protection of the business methods.
III. CONCLUSION
In its intellectual property portfolio, all companies should
aggressively protect their core technology in numerous facets such as
patent protection, copyright, trademarks, maskworks for chip design,
and trade secrets. This is extremely important in the bioinformatics
and biochips arena as ethical issues create an environment against the
patenting of genetic sequence data. In addition to a defensive strategy
of defending its core technology, companies should also pursue an
offensive strategy that includes analyzing emerging standards and
competitor focus so that companies could acquire a competitive
advantage or entice a cross-licensing of another's technology.
44. Regalado, supra note 9, at 51.
